Accelerated irradiation combining electron beam and cobalt sources was carried out in 34 patients with large involved nodes fixed to the cervical structures (N3). Concomitant boost technique was used to reduce the overall duration of treatment from 7 to 5 weeks while maintaining the standard 70-Gy tumor dose. The first part of treatment consisted of conventional cobalt irradiation, 50 Gy delivered to the whole neck over 5 weeks. The accelerated schedule, carried out over 4 weeks, delivered an additional 1 Gy/day to the node through a circular and lateral electron beam field, for a total dose of 70 Gy to the enlarged node. In the case of an identified primary the tumor site was also boosted to the 70-Gy total dose. The rate of acute skin reactions was acceptable and there were no major mucosal complications. At the end of irradiation, 62% of patients experienced complete clinical regression; 41% subsequently had cervical recurrences. Early cervical fibrosis was limited to the over-treated area. The concomitant boost technique is a good way to accelerate irradiation without decreasing the total dose or increasing the immediate complication rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiology.163.3.3575735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipid Levels and Lung Cancer Risk: Findings from the Taiwan National Data Systems from 2012 to 2018.
J Epidemiol Glob Health
January 2025
Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, No.7, Chung Shan S. Rd., Zhongzheng District, Taipei City, 100225, Taiwan.
Background: Lipids are known to be involved in carcinogenesis, but the associations between lipid profiles and different lung cancer histological classifications remain unknown.
Methods: Individuals who participated in national adult health surveillance from 2012 to 2018 were included. For patients who developed lung cancer during follow-up, a 1:2 control group of nonlung cancer participants was selected after matching.
Prophylaxis of HBV reinfection and disease in liver transplanted patients: 2024 update on the role of HBIG and cost-effectiveness evaluation.
Minerva Gastroenterol (Torino)
January 2025
Gastroenterology Department of Emergency and Organ Transplantation, University Hospital Policlinico di Bari, Bari, Italy.
Hepatitis B virus (HBV) infection is a major global health concern, with liver transplantation (LT) serving as a critical treatment for end-stage liver disease caused by HBV. However, the risk of HBV reinfection after LT remains significant, necessitating effective prophylaxis. Today, the combination of hepatitis B immune globulin (HBIG) and high-barrier nucleos(t)ide analogues (NUCs) is the standard of care for preventing HBV recurrence post-LT but concerns about the cost of HBIG and access to high-barrier NUCs have led to a reduction in the use, dose, and duration of HBIG in recent years.
View Article and Find Full Text PDFBackground: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but the prognosis is still poor. PARP inhibitors like olaparib may improve glioblastoma outcomes. We implemented a phase 1-2a trial to assess the safety and efficacy of olaparib combined with standard radio-chemotherapy as a first-line treatment in unresected glioblastoma patients.
View Article and Find Full Text PDFEculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety - a single-center study.
Hematology
December 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Objective: To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.
Method: Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory indicators after 1, 3, and 6 months of eculizumab therapy and at the end of follow-up were documented.
Treatment patterns and clinical profile in progressive pulmonary fibrosis: a Japanese cross-sectional survey.
Front Med (Lausanne)
January 2025
Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Background: There is a paucity of real-world data on patients with interstitial lung diseases (ILDs) that are progressive, other than idiopathic pulmonary fibrosis (IPF), including treatment patterns and attitudes toward treatment. This study aimed to investigate the diagnosis, clinical characteristics, treatment paradigm and current decision-making practices of IPF and progressive pulmonary fibrosis (PPF) in a Japanese real-world setting.
Methods: Data were drawn from the Adelphi Real World PPF-ILD Disease Specific Programme™, a cross-sectional survey with retrospective data collection of pulmonologists and rheumatologists in Japan from April to October 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!